Vitally, even mutant RAS cloned from tumor tissue requires concurrent MYC overexpression for transformation to proceed, highlighting the importance of cooperation between MYCN amplification and oncogenic RAS mutations or activation of RAS-related pathways in neuroblastomas. The gene discussed is MYCN; the disease is neuroblastoma.